Somatrogon shortage — PE supply status & alternatives

Somatrogon

—

🇦🇺 AUST R 349990 · Pfizer Australia Pty Ltd

In supply · Australia

Ngenla®

In supply · 🇦🇺 Australia · short in🌐 PE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Somatrogon
Brand names	Ngenla®
Therapeutic category	Auto-created by DIGEMID — Discontinuidad de Medicamentos (Peru) scraper

Marketing-authorisation holders	Pfizer Australia Pty Ltd

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🌐

DIGEMID · 1h ago

Medium

Verified timeline regulator events

🌐 10 Jan 2026

medium reported

Sources official regulators

🌐

DIGEMID

verified 1h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
NGENLA somatrogon	24 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
NGENLA somatrogon	60 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.